NCT04895358: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
- State
- Under way
- Phase
- Phase 3
- People
- 342 taking part
- Started
- 18 Jun 2021
- Primary completion
- 24 Apr 2026
- Arms
- Pembrolizumab + Chemotherapy
- Results
- None posted
- 20 May 2021: Trial registered
- 18 Jun 2021: Trial started